EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY

ONC201 has exhibited durable tumor regressions in midline high grade glioma patients. G protein-coupled receptor (GPCR) dopamine receptor D2 (DRD2) is overexpressed in high grade gliomas, controls several oncogenic mechanisms, and its antagonism causes tumor cell apoptosis. Using bioinformatic and G...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Benjamin Free, R, Cuoco, Caroline, Prabhu, Varun, Willette, Blair, Day, Marilyn, Anantharaman, Lakshmi, Sulli, Chidananda, Davidson, Edgar, Deacon, Sean, Rucker, Joseph, Charter, Neil, Doranz, Benjamin, Oster, Wolfgang, Stogniew, Martin, Robert Lane, J, Sibley, David, Allen, Joshua
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Experimental Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847112/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.365
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items